Results 151 to 160 of about 2,000 (177)

Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study [PDF]

The Lancet HIV
Summary Background Long-acting treatment for HIV has potential to improve adherence, provide durable viral suppression, and have long-term individual and public health benefits.
J. Eron, S. Little, G. Crofoot, P. Cook, P. Ruane, Dushyantha Jayaweera, Laurie A Vanderveen, E. Dejesus, Yanan Zheng, A. Mills, Hai-Lin Huang, S. Waldman, M. Ramgopal, Linda Gorgos, Sean E. Collins, Jared M. Baeten, M. Caskey   +16 more
semanticscholar   +3 more sources

Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir [PDF]

Expert Opinion on Drug Metabolism and Toxicology
IntroductionLenacapavir is the first HIV-1 capsid inhibitor administered subcutaneously twice yearly. While lenacapavir is currently only indicated as salvage therapy, it has the potential to become a foundation of future treatments and to revolutionize ...
Catia Marzolini, Saye Khoo, Sara Gibbons   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Resistance Analyses in Heavily Treatment-Experienced People with HIV Treated with the Novel HIV Capsid Inhibitor Lenacapavir After 2 years.

Journal of Infectious Diseases
BACKGROUND Lenacapavir is a highly potent first-in-class inhibitor of HIV-1 capsid approved for the treatment of heavily treatment-experienced (HTE) people with HIV-1 (PWH) harboring multidrug resistant (MDR) virus, in combination with an optimized ...
N. Margot, V. Jogiraju, Nina Pennetzdorfer, Vidula Naik, Laurie A Vanderveen, John Ling, Renu Singh, H. Dvory‐Sobol, O. Ogbuagu, Sorana Segal-Maurer, Jean-Michel Molina, Martin S Rhee, Christian Callebaut   +12 more
semanticscholar   +1 more source

Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025

MMWR. Morbidity and mortality weekly report
In 2023, approximately 39,000 persons received a diagnosis of HIV in the United States. Although HIV preexposure prophylaxis (PrEP) is highly effective in preventing HIV infection, acceptance of, adherence to, and persistence taking the available oral ...
Rupa R Patel, Karen W. Hoover, Allison Lale, Janet Cabrales, Katrina M. Byrd, Athena P. Kourtis   +5 more
semanticscholar   +1 more source

Practical Synthesis of 7-Bromo-4-chloro-1H-indazol-3-amine: An Important Intermediate to Lenacapavir [PDF]

Molecules
7-Bromo-4-chloro-1H-indazol-3-amine is a heterocyclic fragment used in the synthesis of Lenacapavir, a potent capsid inhibitor for the treatment of HIV-1 infections.
Frank Gupton, Limei Jin
exaly   +3 more sources

Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.

Annals of Internal Medicine
BACKGROUND Once-weekly oral islatravir plus lenacapavir (ISL+LEN) has the potential to address adherence challenges with daily HIV-1 treatment. OBJECTIVE To evaluate efficacy and safety of once-weekly ISL+LEN.
A. E. Colson, G. Crofoot, P. Ruane, M. Ramgopal, Alexandra W. Dretler, R. G. Nahass, G. Sinclair, M. Berhe, Afsoon Roberts, Shauna Applin, C. Brinson, Dushyantha Jayaweera, Kimberly A. Workowski, Fadi Shihadeh, Shan-Yu Liu, Stephanie O Klopfer, Cyril Llamoso, Sharline Madera, H. Dvory‐Sobol, Martin S. Rhee, E. G. Rhee, Jared M. Baeten, J. Eron   +22 more
semanticscholar   +1 more source

Distinct Target Site of Lenacapavir in Immature HIV-1 and Concurrent Binding with the Maturation Inhibitor Bevirimat

Journal of the American Chemical Society
HIV-1 inhibitors, such as Bevirimat (BVM) and Lenacapavir (LEN), significantly reduce the production and maturation of infectious virions. However, their mechanisms remain unclear due to the absence of high-resolution structures for BVM in complex with ...
Chun-Xiang Wu, Megan E. Meuser, J. Rey, Hamed Meshkin, Rachel Yang, S. Devarkar, Christian Freniere, Jiong Shi, Christopher Aiken, J. Perilla, Yong Xiong   +10 more
semanticscholar   +1 more source

Lessons for long-acting lenacapavir: catalysing equitable PrEP access in low-income and middle-income countries

The Lancet HIV
Despite substantial advances in biomedical HIV prevention, including long-acting injectable pre-exposure prophylaxis (PrEP) options such as cabotegravir, barriers to widespread adoption and scale-up persist in low-income and middle-income countries. Long-
Sharonann Lynch, Rachel M. Cohen, Matthew M. Kavanagh, Agrata Sharma, Y. Raphael, Yogan Pillay, L. Bekker   +6 more
semanticscholar   +2 more sources

Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study

Open Forum Infectious Diseases
Background Lenacapavir is a twice-yearly HIV-1 capsid inhibitor approved, in combination with other antiretrovirals, for the treatment of heavily treatment-experienced people with multidrug-resistant HIV, based on the Phase 2/3 CAPELLA study.
O. Ogbuagu, A. Wiznia, J. McGowan, Daniel S. Berger, C. Creticos, D. Hagins, Theo Hodge, O. Osiyemi, James Sims, David A Wheeler, Hui Wang, N. Margot, H. Dvory‐Sobol, Martin S Rhee, Sorana Segal-Maurer, Jean-Michel Molina   +15 more
semanticscholar   +1 more source

The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic.

Clinical Infectious Diseases
In total, 1.3 million people acquired human immunodeficiency virus (HIV) in 2023, well behind the UNAIDS goal of
Andrew Hill, M. Siedner, Cassandra Fairhead, Francois Venter   +3 more
semanticscholar   +1 more source